BRIEF-Janssen Research & Development reports final Phase 2 data for ibrutinib
December 06, 2016 at 10:57 AM EST
* Phase 2 ibrutinib study in cGVHD showed complete or partial response in up to 2/3 of steroid dependent/refractory patients
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.